AbCellera Biologics (NASDAQ: ABCL) has set the date for the release of its third quarter financial results on Monday 4th November 2024, after market close. Investors and analysts will have a chance to analyze the company's performance during the quarter.
Based on the predictions of financial experts on Wall Street, the establishment is expected to reveal an anticipated $0.15 loss per share for the quarter. Additionally, the firm is poised to disclose a total revenue of $7.95 million for the quarter.
The earnings report for the corresponding quarter of the prior year unveiled a per-share loss of $0.1. This was a direct result of the company's total revenue, which amounted to an impressive $6.6 million during that specific period.
Wall Street analysts have revealed their forecasts for the company's annual performance, predicting a total revenue of $33.6 million. Additionally, they expect the company to report per share loss of $0.58 for the fiscal year.
ABCL will host a conference call with investment community on 4th November 2024 at 05:00 PM eastern time to discuss the financial results.
AbCellera Biologics (ABCL) closed Friday's regular trading session at $2.73, reflecting a 0.00 percent . During the day, ABCL shares traded between $2.72 and $2.80, with a day volume of 1.24 million shares.
